Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2018 6
2019 8
2020 17
2021 13
2022 31
2023 30
2024 32
2025 35
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.
Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, Qu XJ, Qiu H, Zhang YJ, Ying JE, Zhang J, Sun LY, Lin RB, Wang C, Liu H, Qiu MZ, Guan WL, Rao SX, Ji JF, Xin Y, Sheng WQ, Xu HM, Zhou ZW, Zhou AP, Jin J, Yuan XL, Bi F, Liu TS, Liang H, Zhang YQ, Li GX, Liang J, Liu BR, Shen L, Li J, Xu RH. Wang FH, et al. Cancer Commun (Lond). 2024 Jan;44(1):127-172. doi: 10.1002/cac2.12516. Epub 2023 Dec 31. Cancer Commun (Lond). 2024. PMID: 38160327 Free PMC article.
For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti-angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)-positive and defic …
For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti-angiogenic …
Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.
Ooki A, Osumi H, Yoshino K, Yamaguchi K. Ooki A, et al. Gastric Cancer. 2024 Sep;27(5):907-931. doi: 10.1007/s10120-024-01523-4. Epub 2024 Jun 26. Gastric Cancer. 2024. PMID: 38922524 Free PMC article. Review.
Most MSI-H/dMMR GCs arise sporadically, mainly due to MutL homolog 1 (MLH1) epigenetic silencing. ...However, a subset of MSI-H/dMMR GC patients does not benefit from immunotherapy, highlighting the need for further research into p …
Most MSI-H/dMMR GCs arise sporadically, mainly due to MutL homolog 1 (MLH1) epigenetic silencing. ...However, a subset …
Biology-guided deep learning predicts prognosis and cancer immunotherapy response.
Jiang Y, Zhang Z, Wang W, Huang W, Chen C, Xi S, Ahmad MU, Ren Y, Sang S, Xie J, Wang JY, Xiong W, Li T, Han Z, Yuan Q, Xu Y, Xing L, Poultsides GA, Li G, Li R. Jiang Y, et al. Nat Commun. 2023 Aug 23;14(1):5135. doi: 10.1038/s41467-023-40890-x. Nat Commun. 2023. PMID: 37612313 Free PMC article.
We validate the model for predicting prognosis of gastric cancer and the benefit from adjuvant chemotherapy in a multi-center international study. ...Importantly, our model identifies a subset of mismatch repair-deficient tumors that are non-res …
We validate the model for predicting prognosis of gastric cancer and the benefit from adjuvant chemotherapy in a multi-center …
Helicobacter pylori and immunotherapy for gastrointestinal cancer.
Jia K, Chen Y, Xie Y, Wang X, Hu Y, Sun Y, Cao Y, Zhang L, Wang Y, Wang Z, Lu Z, Li J, Zhang X, Shen L. Jia K, et al. Innovation (Camb). 2024 Jan 8;5(2):100561. doi: 10.1016/j.xinn.2023.100561. eCollection 2024 Mar 4. Innovation (Camb). 2024. PMID: 38379784 Free PMC article.
Transcriptomic analysis revealed that H. pylori-positive GC shared molecular characteristics similar to those of immunotherapy-sensitive GC. However, H. pylori-positive patients with DNA mismatch repair-deficient (dMMR)/microsatellite instabilit …
Transcriptomic analysis revealed that H. pylori-positive GC shared molecular characteristics similar to those of immunotherapy-sensit …
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, Palermo F, De Manzoni G, Bencivenga M, Bittoni A, Chiodoni C, Lorenzini D, Todoerti K, Manca P, Sangaletti S, Prisciandaro M, Randon G, Nichetti F, Bergamo F, Brich S, Belfiore A, Bertolotti A, Stetco D, Guidi A, Torelli T, Vingiani A, Joshi RP, Khoshdeli M, Beaubier N, Stumpe MC, Nappo F, Leone AG, Pircher CC, Leoncini G, Sabella G, Airo' Farulla L, Alessi A, Morano F, Martinetti A, Niger M, Fassan M, Di Maio M, Kaneva K, Milione M, Nimeiri H, Sposito C, Agnelli L, Mazzaferro V, Di Bartolomeo M, Pietrantonio F. Raimondi A, et al. Ann Oncol. 2025 Mar;36(3):285-296. doi: 10.1016/j.annonc.2024.11.016. Epub 2024 Dec 3. Ann Oncol. 2025. PMID: 39637944 Free article. Clinical Trial.
BACKGROUND: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit from chemotherapy. Immunotherapy may eliminate the need for chemotherapy or surgery. PATIENTS AN …
BACKGROUND: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers im …
The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.
Pu W, Li S, Zhang J, Huang J, Li J, Jiang Y, Xu Z, Yi F, Lan Y, Xiao Q, Chen W, Jin J. Pu W, et al. Front Immunol. 2025 Mar 26;16:1566939. doi: 10.3389/fimmu.2025.1566939. eCollection 2025. Front Immunol. 2025. PMID: 40207218 Free PMC article.
BACKGROUND: Immune checkpoint inhibitors (ICIs) plus fluorouracil-based chemotherapy (Chemo) have been approved as an initial treatment strategy for metastatic or recurrent human epidermal growth factor receptor 2 (HER2)-negative gastric cancer (GC) or gastroesop …
BACKGROUND: Immune checkpoint inhibitors (ICIs) plus fluorouracil-based chemotherapy (Chemo) have been approved as an initial treatment stra …
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. Chao J, et al. JAMA Oncol. 2021 Jun 1;7(6):895-902. doi: 10.1001/jamaoncol.2021.0275. JAMA Oncol. 2021. PMID: 33792646 Free PMC article.
IMPORTANCE: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors. ...MAIN OUTCOMES AND MEASURES: Response was assessed centrally using Response Evaluati …
IMPORTANCE: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsat …
Immunotherapy in Gastrointestinal Malignancies.
Mizrahi J, Pant S. Mizrahi J, et al. Adv Exp Med Biol. 2020;1244:93-106. doi: 10.1007/978-3-030-41008-7_5. Adv Exp Med Biol. 2020. PMID: 32301012 Review.
There are subsets of patients for whom immunotherapy has been FDA approved in recent years. For example, anti-PD-1 therapy is approved for patients with pretreated hepatocellular carcinoma. Additionally, patients with PD-L1-positive gastric cancer are eligibl …
There are subsets of patients for whom immunotherapy has been FDA approved in recent years. For example, anti-PD-1 therapy is approve …
TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity.
Niu Y, Ding C, Wang Q, Yin J, Li L, Liu W, Wang X, Huang L. Niu Y, et al. J Exp Clin Cancer Res. 2025 Aug 15;44(1):242. doi: 10.1186/s13046-025-03513-5. J Exp Clin Cancer Res. 2025. PMID: 40817248 Free PMC article.
BACKGROUND: Gastric cancers are classified into four molecular subtypes according to The Cancer Genome Atlas (TCGA) classification: Epstein-Barr virus-positive (EBV-positive), microsatellite instability-high (MSI-H), chromosomal instability (CIN), and genomically st …
BACKGROUND: Gastric cancers are classified into four molecular subtypes according to The Cancer Genome Atlas (TCGA) classification: Epstein- …
Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer.
Yan SY, Fan JG. Yan SY, et al. World J Gastroenterol. 2024 Jun 7;30(21):2734-2739. doi: 10.3748/wjg.v30.i21.2734. World J Gastroenterol. 2024. PMID: 38899328 Free PMC article.
There are four principal strategies for tumor immunotherapy: ICIs, tumor vaccines, adoptive immunotherapy and nonspecific immunomodulators. ...Recent studies have revealed that MSI-high or mismatch- repair-deficient tumors, regardless of their p …
There are four principal strategies for tumor immunotherapy: ICIs, tumor vaccines, adoptive immunotherapy and nonspecific immu …
189 results